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A B S T R A C T
Fungisome® (F), a liposomal amphotericin B (AmB) product, is marketed in India as a safe and eﬀective ther-
apeutic for the parasitic infection visceral leishmaniasis. Its potential in the treatment of cutaneous leishmaniasis
(CL), a disﬁguring form of the disease aﬀecting the skin, is currently unknown. Here, we report the evaluation of
the eﬃcacy of F in the Leishmania major BALB/c murine model of CL, including a head-to-head comparison with
the standard liposomal AmB formulation AmBisome® (A). Upon intravenous administration at dose levels of 5,
10 and 15mg/kg of body weight (on days 0, 2, 4, 6 and 8), F showed clear signs of toxicity (at 15mg/kg), while
A did not. After complete treatment (day 10), the tolerated doses of 5 and 10mg/kg F had signiﬁcant antil-
eishmanial activity (ED50=4.0 and 12.8mg/kg for qPCR-based parasite load and lesion size, respectively),
although less than that of A at identical doses (ED50= 3.0 and 8.8 mg/kg). The eﬃcacy of F was inferior
compared to A because lower levels of the active agent AmB accumulated within the infected lesion. In con-
clusion, despite possibly being less safe and eﬃcacious than A at equivalent doses, the moderate in vivo activity
of F could indicate a role in the systemic pharmacotherapy of CL.
1. Introduction
With more than 2 million new cases per year and 350 million people
at risk in over 100 countries, leishmaniasis is a major public health
problem aﬀecting the poorest of the poor in many parts of the world
(Alvar et al., 2012). Leishmaniasis is a disease complex caused by over
20 species of the protozoan parasite Leishmania that are transmitted via
female sand ﬂies. Diﬀerent types include visceral leishmaniasis (VL,
also known as kala-azar, an often fatal-if-not-treated condition of the
reticuloendothelial system predominantly caused by L. donovani), and
the most common form, cutaneous leishmaniasis (CL). In simple CL,
skin lesions caused by species such as L. major or L. mexicana are lo-
calized and self-healing, but leave disﬁguring wounds and scars. In-
fections by other species can lead to rare but severe chronic, diﬀuse or
mucosal CL symptoms (complex CL) (Reithinger et al., 2007). Another
form in the clinical spectrum of skin syndromes is post-kala-azar-dermal
leishmaniasis (PKDL), a complication of VL where recovered,
otherwise-healthy patients develop pigmentation disorders and a dif-
fuse macular or nodular rash (Zijlstra et al., 2003).
For CL, the pentavalent antimonials sodium stibogluconate
(Pentostam®) and meglumine antimoniate (Glucantime®) remain the
standard treatment, despite being associated with a painful and lengthy
series of injections, severe side eﬀects and variable treatment outcomes
(Aronson et al., 2016). One of the available second-line drugs is the
intravenous (IV) polyene antibiotic amphotericin B (AmB), which kills
Leishmania through pore formation after complexation with ergosterol
in its cell membrane (Cohen, 2016). The clinical use of the conventional
deoxycholate salt form is limited by infusion-related side eﬀects such as
fever and rigor, as well as chronic toxicity (Tonin et al., 2017). AmBi-
some® (A), a liposomal formulation of AmB, is better tolerated and ef-
fective against VL in single high dose (7.5–10mg/kg, Mondal et al.,
2014) and in multiple doses against CL (3mg/kg daily for a total of
21mg/kg, Wortmann et al., 2010) and PKDL (two cycles of 4×5mg/
kg, Basher et al., 2017). Despite A being listed on the World Health
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Organisation Essential Medicines List, the requirement for cold chain
and the high price (at least 18 $ per vial via donation programmes)
often make availability and access in primary health care settings
problematic (Bhattacharya and Ali, 2016). Fungisome® (F) is the brand
name of an alternative liposomal AmB formulation developed and
commercialized since 2003 in India (Sanath et al., 2005). F contains
diﬀerent lipids and has a diﬀerent formulation, vesicle size, preparation
and pharmacokinetic proﬁle compared to A (Kshirsagar, 2014). As-
suring pharmaceutical and/or biological equivalence of F to A is com-
plicated because of a lack of clear regulatory guidelines on liposomal
generics (Gaspani, 2013). Clinical studies reported eﬀectiveness and
safety of F in VL (Bodhe et al., 1999; Mondal et al., 2010) and recent
phase II trials have demonstrated > 90% cure rates following short (2
days) or single high dosed (10mg/kg) therapy (Sundar et al., 2015;
Goswami et al., 2016).
A has been used to treat patients with simple (Guery et al., 2017)
and mucosal (Rocio et al., 2014) CL. To investigate the pharmacology of
A in CL, we have recently applied an approach based on pharmacoki-
netic pharmacodynamic (PK PD) relationships in mice (Wijnant et al.,
2018). For F, in contrast, there is no such information available to
describe the link between drug levels in the infected skin and ther-
apeutic outcomes. This is not only a crucial consideration for potential F
treatment of CL, but also of PKDL (for which no animal models of
disease are available, Desjeux et al., 2013). Our aim was therefore to (i)
evaluate the intralesional drug accumulation and eﬃcacy of in-
travenously administered F at three dose levels in the L. major BALB/c
murine model of CL and (ii) provide a head-to-head comparison with
the standard liposomal AmB formulation A.
2. Materials and methods
2.1. Drugs
Sealed vials of Fungisome® (F, Lifecare Innovations, India) were
sonicated in a Camlab TransSonic T460/H water bath for 45min at
25 ± 5 °C to transform the large multilamellar vesicles
(2700–3500 nm, Serrano et al., 2013) into smaller unilamellar lipo-
somes (≈220 nm, Jadhav et al., 2011), as per the manufacturer's in-
structions. For AmBisome® (A, Gilead, UK), 12ml sterile water was
added to the lyophilized powder to reconstitute the unilamellar lipo-
somes (≈70 nm, Walsh et al., 1998; Dupont, 2002), also following the
manufacturer's protocol. Saline 0.85% and dextrose 5% were used to
dilute stocks of F and A respectively to the desired concentrations.
Paromomycin sulphate (Sigma, UK) was prepared in phosphate buf-
fered saline (PBS). Dilutions were prepared one day before starting the
experiment and stored at 4 °C in the dark.
2.2. Murine model of CL
L. major MHOM/SA85/JISH118 parasites were cultured in
Schneider's insect medium (Sigma, UK) supplemented with 10% heat-
inactivated fetal calf serum (HiFCS, Sigma UK). These were passaged
each week at a 1:10 ratio of existing culture to fresh media in 25ml
culture ﬂasks without ﬁlter and incubated at 26 °C. Stationary phase
parasites were centrifuged for 10min at 2100 rpm and 4 °C. The su-
pernatant was removed and the pellet re-suspended in RPMI medium
(Sigma, UK). Cell number was estimated by microscopic counting with
a Neubauer haemocytometer. Female BALB/c mice around 6–8 weeks
old were purchased from Charles River Ltd. (Margate, UK). These mice
were kept in humidity- and temperature controlled rooms (55–65% and
25–26 °C, respectively) and fed water and rodent food ad libitum. After
acclimatization for 1 week, mice were randomized and subcutaneously
(s.c.) injected in the shaven rump above the tail with 200 μl of a
parasite suspension containing 4× 107 low-passage-number (p < 5),
stationary-phase L. major promastigotes in RPMI medium. Twelve days
later, when a 5- to 6-mm non-ulcerating nodule had formed, mice were
allocated to the diﬀerent experimental arms to ensure comparable le-
sion sizes in each group. All animal experiments were conducted under
licence X20014A54 according to UK Home Oﬃce regulations under the
Animals (Scientiﬁc Procedures) Act 1986 and EC Directive 2010/63/E.
2.3. Treatment and sample collection
L. major -infected BALB/c mice (n= 4–5 per group) each received
an intravenous bolus (200 μl) of A or F at 5, 10, 15 mg/kg or 0.85%
saline (untreated negative control, (−)) over a 1–2min period on days
0, 2, 4, 6 and 8. The dosing regimen for F and A was based on earlier
data on the eﬃcacy of A in the L. major-BALB/c model of CL (Wijnant
et al., 2018). Due to previous reports of F's toxicity, the dose of 15mg/
kg was not exceeded (Szoka et al., 1987). The positive control group
(+) received 10 daily doses of intraperitoneal (IP) 50 mg/kg par-
omomycin, a regimen with proven eﬃcacy in this CL model (Wijnant
et al., 2017; El-On and Hamburger, 1987). On day 10, the experiment
was terminated, animals were sacriﬁced and lesion skin samples were
collected.
2.4. Measurement of lesion size and intralesional AmB levels
The methodologies to determine lesion size, homogenize skin sam-
ples and measure intralesional AmB levels have been described in full
detail in earlier publications (Wijnant et al., 2018). Samples in this
study were treated identically. In brief, lesion size (average of width
and length) was measured daily during treatment using digital callipers.
On day 10, animals were sacriﬁced and the collected lesions were
ground mechanically with zirconium oxide beads in 1ml of PBS. The
drug (AmB) was then extracted from tissue homogenates with 84:16
methanol:DMSO, followed by LC-MS/MS quantiﬁcation.
2.5. Measurement of parasite load
A 2-step RT qPCR was used to determine parasite load in murine CL
lesions. RNA from a 200 μl volume of skin homogenate was extracted
using the GRS FullSample Puriﬁcation kit (Grisp Research Solutions,
Portugal). Brieﬂy, samples were lysed, DNA was removed via a genomic
DNA mini spin column and the collected ﬂow-through was transferred
to an RNA mini spin column and processed following the manufac-
turer's protocol. After washing, RNA was eluted from the column with
30 μl RNase-free water. Quality and purity of the RNA extract was es-
timated with a Nanodrop ND1000 (Thermo Fisher Scientiﬁc, USA). To
avoid contamination or degradation of RNA, all workbench surfaces
and materials were cleaned with RNase AWAY® (Thermo Fisher, USA)
and samples kept on ice and stored at −80 °C until further use.
Complementary DNA (cDNA) was then generated from 10 μl of the
RNA-extract using the iScript™ cDNA Synthesis Kit (Bio-Rad, USA) on a
T100 Thermal Cycler (Bio-Rad, USA) according to the manufacturer's
instructions. TaqMan qPCR reactions of 10 μl were performed in du-
plicate including 2 μl of cDNA, 5 μl GRISP Xpert Fast PROBE master mix
(Grisp Research Solutions, Portugal), 0.25 μM probe (StabVida,
Portugal) and 0.4 μM of each primer in 96-well PCR plates (VWR,
Portugal). Assays were performed in a CFX Connect™ Real-Time PCR
Detection System (Bio-Rad, USA). Cycling conditions were as follows:
40 cycles at a denaturation setting of 95 °C for 5min followed by a two-
step ampliﬁcation cycle of 95 °C for 10 s and 60 °C for 30 s. Each run
included triplicates of a negative control, a no template control and the
calibration standards (L. major DNA from 108 to 102 parasites). Bio-Rad
CFX Manager 3.1 software was used for analysis. The lower limit of
detection was 100 parasites. The qPCR methodology (based on ampli-
ﬁcation of the 18S ribosomal Leishmania region), probe and primer
sequences (Van Der Meide et al., 2008) and preparation of calibration
standards were as described before (Wijnant et al., 2017).
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2.6. Dose-response curves
Non-linear ﬁt models (log(agonist) versus normalized response with
variable slope) in GraphPad Prism version 7.02 were used to calculate
ED50 and LD50 data. Response in treated groups was expressed as re-
lative reduction compared to untreated controls ((signal untreated –
signal treated)/signal untreated× 100%).
2.7. Statistical analysis
Analysis of variance (ANOVA) assuming Gaussian distribution (one-
way for parasite load and intralesional AmB level, repeated measures
for lesion size) followed by Tukey's multiple comparison tests was used
to analyse diﬀerences between groups. All data is presented as means
and standard deviation (SD). A p - value<0.05 was considered sta-
tistically signiﬁcant. All analyses were performed using GraphPad
Prism version 7.02.
3. Results
3.1. Toxic eﬀects of F and A
After L. major-infected mice (n=5) received slow infusions of 5, 10
or 15mg/kg of either F or A (200 μl over 2min), no direct adverse
eﬀects and signs of acute toxicity were observed during the ﬁrst 30min
or 24 h after dosing. However, 48 h after drug administration (day 2),
one mouse in the 10mg/kg F and two mice in the 15mg/kg F group had
died. Among the surviving animals, which had been similarly dosed
again on day 2, two more mice in the 15mg/kg F died 24 h later. By day
3, the one surviving mouse in this highest dose F group showed signs of
a hunched posture, pilo-erection and weight loss (data not shown) and
it was humanely sacriﬁced by CO2. No signs of potential CL-related
mortality such as severe ulceration, dissemination of the lesion or he-
patosplenomegaly (which could confound the cause of death) were
observed during autopsies of these F-treated mice. In contrast, in the
mice dosed with A (all three dose levels), F (5 and 10mg/kg) and ne-
gative and positive controls, no fatalities were seen during the rest of
treatment.
3.2. Eﬃcacy of F and A
3.2.1. Lesion size
The eﬀect of F and A on lesion size over the course of the 10-day IV
treatment in the L. major –BALB/c model of CL is shown in Fig. 1a.
Compared to the untreated controls (−), the lesion size for F was sig-
niﬁcantly lower in 5 mg/kg and 10 mg/kg groups (p = 0.0007 and
0.0002, respectively). Signiﬁcant reductions in lesion size were also
found for A at all dose levels (p < 0.0005). When the activity of A and
F were compared at identical dose levels, diﬀerences in lesion size were
not signiﬁcant (5 mg/kg: p = 0.99, 10 mg/kg: p = 0.48). No direct
comparison between F and A could be made for 15 mg/kg, due to the
lethal eﬀects at this dose level for F. Reductions in lesion size in lipo-
somal AmB-treated groups were lower when compared to those in the
positive control (+).
3.2.2. Parasite load
The eﬃcacy of F and A, as evaluated by RT qPCR parasite load on
day 10, is shown in Fig. 1b. Compared to the untreated controls,
parasite load was lower in the 5 mg/kg and 10 mg/kg F groups, but the
diﬀerences were not signiﬁcant (p = 0.51 and 0.06 respectively). In
contrast, increasing doses of A resulted in signiﬁcant reductions in
parasite load (all p-values< 0.05). At identical dose levels, the diﬀer-
ences between A and F in parasite load were not signiﬁcant (5 mg/kg:
p = 0.39, 10 mg/kg: p = 0.99) and again, no comparison could be
made at 15 mg/kg due to toxicity of F at this dose level. All liposomal
AmB-treated groups had lower parasite load reductions compared to
the positive control (+), except for the highest dose of A where there
was no signiﬁcant diﬀerence (p > 0.999).
3.2.3. Intralesional amphotericin B levels
We determined the drug levels of the active compound AmB within
the infected lesion at the end of the experiment (Fig. 1c). At identical
dose levels of 5 and 10 mg/kg, intralesional AmB levels were lower for
F than for A, but the diﬀerences between the groups were not sig-
niﬁcant (p = 0.96 and 0.18, respectively). Due to fatal toxicity of F at
15 mg/kg, no direct comparison with A could be made at this dose
level. As expected, no AmB was detectable in samples from untreated
(−) and positive controls (+).
3.3. Therapeutic window of F and A
After the logarithm of the dose level was plotted against percentage
response for A and F (data from toxicity section and Fig. 1), 50% and
90% eﬀective (ED) and lethal (LD) doses were calculated (Table 1).
Based on the number of lethal events per group over the course of drug
administration (A: 0/5 for 5, 10 and 15mg/kg; F: 0/5 for 5mg/kg, 1/5
for 10mg/kg, 4/5 for 15mg/kg F), LD50 and LD90 could not be calcu-
lated for A, but were found to be 12.3 and 16.9mg/kg for F. Both 50%
and 90% eﬀective doses for parasite load and lesion size were higher for
F than for A, indicating inferior eﬃcacy. Therapeutic indices (LD/ED)
were over 10-fold lower for F compared to A.
4. Discussion
The liposomal multilamellar amphotericin B (AmB) formulation
Fungisome® (F) is intravenously administered after sonication for the
treatment of VL (Goswami et al., 2016). Little is known about its po-
tential role in CL pharmacotherapy. Here, we evaluated eﬃcacy, toxi-
city and intralesional drug accumulation of F in direct comparison to
the standard liposomal AmB product AmBisome® (A) in the L. major-
BALB/c model of CL.
Compared to A, F was more toxic and less eﬃcacious; thus, it had a
narrower therapeutic index. As the main aim of this work was to
evaluate eﬃcacy and not toxicity, we did not perform dose-escalating
studies. However, LD50 values were still calculable as multiple un-
expected fatal events occurred at the highest dose of F. The observed
LD50 for F (12.3mg/kg) likely underestimates its safety window, as
other researchers found a higher murine LD50 (17mg/kg, Szoka et al.,
1987) and doses up to 10–15mg/kg are tolerated by patients (Sundar
et al., 2015). Chronic side eﬀects of the active compound AmB (such as
nephrotoxicity, hepatotoxicity and anaemia) were plausible causes of
death in the 15mg/kg F group, because the lipids of the F liposome are
non-toxic (Kshirsagar et al., 2005) and we saw no typical signs of acute
AmB overdose in mice (convulsions followed by coma). Although F
might be more toxic than A (possibly due to higher uptake in the kidney
and/or liver, or increased leakage of AmB from the liposome to the
blood), its LD50 is still 5-fold higher than that of non-liposomal AmB
deoxycholate (LD50= 2.3mg/kg, Szoka et al., 1987).
F was mildly eﬃcacious at 5×5mg/kg and 5×10mg/kg, as it
caused a signiﬁcant suppressive eﬀect on lesion development, despite a
non-signiﬁcant reduction in parasite loads. The inferior eﬃcacy of F
compared to A could be related to lower intralesional drug concentra-
tions. Levels of AmB in the infected skin have been shown to correlate
well to therapeutic outcomes (Wijnant et al., 2018), which can be ex-
pected because of the concentration-dependency of its antimicrobial
activity (Lestner et al., 2010). The higher accumulation of A over F at
the infected skin site could be explained by diﬀerences in a number of
physicochemical and pharmacokinetic parameters between the two
formulations. After intravenous administration of A, 97% of AmB in the
bloodstream remains liposome-associated during the ﬁrst 4 h (Bekersky
et al., 2002) and systemic exposure levels are high (1mg/kg:
Cmax≈ 10 μg/ml, AUC≈70 μg.h/ml in mice, Wijnant et al., 2018). The
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small liposome size (≈70 nm) could facilitate extravasation through
the leaky capillaries in the inﬂamed lesion skin (Romero and Morilla,
2008), followed by uptake by the parasitized dermal macrophages.
Alternatively, phagocytic monocytes in the blood could carry ingested
A while migrating to the infection site (Voak et al., 2017). In contrast to
A, the liposomal stability of F in plasma is unknown (possibly releasing
‘free’ AmB after interaction with (lipo)proteins, Romero and Morilla,
2008) and its systemic exposure is 7- fold lower (1mg/kg: Cmax≈1 μg/
ml, AUC≈11 μg.h/ml in humans, Gokhale et al., 1993). The 3-fold
larger size of F (≈220 nm) compared to A enhances its clearance by the
reticuloendothelial system following opsonin-coating (80% of the total
F dose accumulates in the liver within 30min, Jadhav et al., 2011;
Ownes and Peppas, 2006), and could possibly also aﬀect the size-de-
pendent processes of extravasation (Poh et al., 2015), macrophage
uptake (Champion et al., 2008) and drug retention in tissues (Tang
et al., 2014). The dependency of the ﬁnal diameter of the small uni-
lamellar F liposomes on the water bath equipment (type, condition,
settings) used for sonication of the multilamellar vesicles could be a
concern for safety and quality-assurance. The importance of a strict
manufacturing process to control particle size is illustrated by the in-
creased toxicity of other liposomal AmB products Anfrogen and Lambin
compared to A, even though their lipid composition is identical. Of the
several generic liposomal AmB formulations currently available, F is the
only one that has been tested in clinical trials for the treatment of
(visceral) leishmaniasis (Adler-Moore et al., 2016).
Our data has implications for both the clinical use of F and drug
development for CL. The relatively small scale (n= 4–5), murine model
of L. major CL (non-cure BALB/c rather than self-curing C57BL/6) and
single tested treatment regimen (5 alternate day administrations over
10 days) are limitations of this work. However, the lower tolerated
doses, inferior eﬃcacy and much smaller therapeutic window of F
compared to A we observed in our murine study might indicate an
increased risk of CL treatment failure and/or duration. The proof of low
but signiﬁcant drug accumulation of F in L. major skin lesions and al-
ready known activity against L. donovani in VL raises the possibility of
use in PKDL treatment, be it with similar caveats as for CL. However,
the immunological and histopathological nature of the inﬂammatory
skin response in PKDL is diﬀerent compared to that of localized CL
(Mondal et al., 2010; Scott and Novais, 2016; Nylén and Eidsmo, 2012),
which could aﬀect the pharmacokinetics of liposomal formulations.
Finally, many researchers over the last decades have proposed the en-
capsulation of antileishmanial drugs into liposomes as a strategy for
passive targeting of the CL infection site (Gutiérrez et al., 2016). The
data in the present study suggests an advantage for smaller liposomes
(70 > 220 nm) with higher stability and exposure in the bloodstream
after IV administration.
In conclusion, F could play a minor role in the systemic treatment of
(mainly complex) CL, as we observed moderate eﬃcacy in a murine
disease model. However, compared to A, the therapeutic index was
narrower and the in vivo activity was inferior due to lower levels of the
active compound AmB delivered to the infected lesion site. Future re-
search should also investigate the eﬀects of the alternative topical
formulation Fungisome® Gel (Lifecare Innovations), as it has potential
for local treatment for simple, small CL lesions with little risk of com-
plication.
Fig. 1. Comparative eﬃcacy of the liposomal amphotericin B (AmB) formulations AmBisome® (A) and Fungisome® (F) in the L. major-BALB/c model of CL. Mice
received 10 doses of 50 mg/kg paromomycin (IP, (+)) or ﬁve doses of either 0.85% saline (untreated negative control (−)) or 5, 10 and 15 mg/kg F and A (IV).
During treatment, lesion size was measured daily (a). On day 10, lesion skin samples were collected and parasite load (b) and AmB levels (c) in the tissue were
evaluated. The photo on the bottom shows the CL lesions (arrow) on the rump of the mice on day 10. Each point represents the mean ± SD (n = 4–5 per group).
ANOVA (1-way for parasite load and intralesional AmB level, repeated measures for lesion size) followed by Tukey's multiple comparison tests was used to analyse
diﬀerences between untreated controls and experimental groups. A p-value<0.05 was considered statistically signiﬁcant (*: p < 0.05, **: p < 0.001, ***:
p < 0.0005, ****: p<0.0001), p> 0.05 not signiﬁcant (no marking above bar). †: day of sacriﬁce. Skull: no data available due to lethal toxicity at this dose level.
N/A: not applicable.
Table 1
50% and 90% eﬀective (ED) and lethal (LD) doses (mg/kg) for the liposomal
amphotericin B (AmB) formulations AmBisome® (A) and Fungisome® (F) in the
L. major-BALB/c model of CL, based on toxicity and Fig. 1 data. The number of
lethal events per group over the full course of treatment was monitored during
treatment for calculation of LD values. At day 10, parasite load (PL) and lesion
size (LS) were determined and eﬀect expressed as relative percentage of re-
duction compared to the untreated control group, which was used to calculate
ED values. Therapeutic indices (TI) were calculated as the LD over ED ratio. As
no lethal events occurred for A at the tested dose levels, reference LD values
from mice (*) were used from the AmBisome® FDA pharmacological review
document, application number 050740 (Drug Approval Package).
AMBISOME® FUNGISOME®
50% 90% 50% 90%
LD 133.0* 150.0* 12.3 16.9
EDPL 3.0 4.5 4.0 11.0
EDLS 8.8 51.3 12.8 102.8
TIPL 44.9 33.0 3.1 1.5
TILS 15.1 2.9 1.0 0.2
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